Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextenza in Ocular Graft Versus Host Disease
NCT04728646Phase 4Withdrawn
- Sponsor
- Massachusetts Eye and Ear
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ozurdex in graft versus host disease (GVHD), sponsored by Massachusetts Eye and Ear. Planned start Sep 2021; status: withdrawn.
02
Drugs
ozurdex
03
Conditions
graft versus host disease (GVHD)
Beyond the preview
Go deeper on NCT04728646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04728646.